Navigation Links
Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Date:1/7/2008

ne antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R). The preclinical profile of TR-701 has been documented in a series of presentations at the recent ICAAC conference and can be accessed at the Trius website. Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipeline includes three additional structure-based drug design programs directed against novel antibacterial targets. For more information, visit http://www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
2. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... ITCA 650 (continuous subcutaneous delivery of exenatide) in type ... the 50 th Annual Meeting of the European ... the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed ... poorly controlled type 2 diabetes. The results were presented ...
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
(Date:9/18/2014)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... 30, 2014. Quarter Ended June 30, ... 2014 increased $492,000, or 18%, to $3.2 million from ... 2013, due primarily to an increase of $746,000 in ... largest customer, partially offset by an aggregate decrease in ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13
... Carnegie Mellon University,s Bone Tissue Engineering Center ... limbs in combat. (Logo: http://photos.prnewswire.com/prnh/20020422/CMULOGO) ... Hollinger, director of the center, and Professor Krzysztof ... Department of Defense research grant to develop a ...
... Stanley M. Chesley of the Cincinnati, Ohio-based law firm of ... a major class action lawsuit against DePuy Orthopaedics, Inc. and ... Johnson and Johnson recently recalled over 90,000 ASR XL Acetabular ... causing patients to undergo hip replacement surgery. ...
Cached Medicine Technology:CMU's Bone Tissue Engineering Center Receives Defense Department Research Grant to Help Injured Soldiers 2
(Date:9/19/2014)... More states are passing legislation permitting or requiring schools ... child having a severe allergic reaction. Epinephrine auto-injectors ... that can lead to throat swelling, breathing difficulties, a ... In people with severe allergies to certain foods, ... certain drugs, anaphylaxis can occur within moments of exposure ...
(Date:9/19/2014)... Wisconsin (MCW) scientists has identified a new gene associated with ... humans. The findings are published in the September issue of ... Ph.D., associate professor of pediatrics at MCW and a researcher ... study and is the corresponding author of the paper. , ... in which a variant was associated with fasting glucose levels ...
(Date:9/19/2014)... September 19, 2014 BCC Research reveals ... AND GLOBAL MARKETS , the global market for human ... billion by 2018, with a five-year compound annual growth ... is growing at a steady 3.8% CAGR. , Given ... lower sales, coupled with the incidence of increasing mortality ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 Ticket ... presale tickets for her 2015 “Honeymoon” Tour. This ... ARIANA-2015 for additional savings at the checkout. , Ariana Grande ... MO (Independence Event Center) , Feb. 28, 2015: Milwaukee, WI ... MN (Xcel Energy Center) , March 03, 2015: Chicago, IL ...
(Date:9/19/2014)... from the wonder material graphene has been used to ... cancer. , The biosensor has been shown to ... tests currently in use, and was able to provide ... possibility of a rapid, point-of-care diagnostic tool for patients. ... in IOP Publishing,s journal 2D Materials . , ...
Breaking Medicine News(10 mins):Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4Health News:Graphene sensor tracks down cancer biomarkers 2
... and public campaigner, has made known the fact that she ... , Dame Anita known worldwide for her company, ... was infected with the virus in 1971 via infected blood, ... businesswoman who is well known for her indefatigable campaigning has ...
... Organization (PAHO) are working with health authorities in Paraguay ... has affected a// number of communities throughout the nation ... America. ,PAHO officials warn that the entire ... prepare for what promises to be a "difficult year" ...
... A recent study by scientists at University of Wisconsin-Madison ... hear better. ,Led by Ruth Litovsky, an ... suggests that deaf children who have a cochlear implant ... use both implants instead of one. Children with two ...
... treatment for an abdominal aortic aneurysm, a weak spot ... time. If the vessel ruptures suddenly before surgery to ... scientists say they have identified a key enzyme that ... growth of aneurysms. Their finding raises hopes for developing ...
... omega-3 fatty acids on their own can alleviate depression, ... there is only limited evidence that they can relieve ... adds. ,Evidence from circumstantial research has suggested ... such as depression. And the findings have attracted widespread ...
... bottle-fed children, reveals a large, long term study, published// ahead ... ,Over 3000 children from 16 rural and urban areas ... of the Boyd Orr Study of Diet and Health in ... on 1414 people in their 60s and 70s, for whom ...
Cached Medicine News:Health News:Body Shop Founder’s New Project-against Hepatitis 2Health News:PAHO Urges Readiness for Dengue Outbreaks in 2007 2Health News:Cochlear Implants in Both Ears Enables Better Hearing 2Health News:Cochlear Implants in Both Ears Enables Better Hearing 3Health News:Enzyme Critical for Early Growth of Abdominal Aortic Aneurysms 2Health News:Enzyme Critical for Early Growth of Abdominal Aortic Aneurysms 3
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: